Syros Pharmaceuticals

Yahoo Finance • 10 months ago

Syros Highlights Anticipated 2024 Milestones to Deliver on the Value of Tamibarotene

-- On-Track to Complete Enrollment of 190 patients for Primary Analysis in SELECT-MDS-1 Phase 3 Trial in 1Q 2024; Pivotal CR Data Expected by Mid-4Q 2024 -- -- Additional Data from SELECT-AML-1 Phase 2 Trial Expected in 2024; Initial Data... Full story

Yahoo Finance • 2 years ago

Syros Pharmaceuticals Announces Publication in Blood Advances Demonstrating the Potential of Tamibarotene in Patients with RARA Gene Overexpression, Supporting Ongoing Clinical Development in AML and MDS

Combination of tamibarotene and azacitidine in a Phase 2 trial demonstrated a high complete response rate, with rapid onset and clinically meaningful durability in newly diagnosed unfit acute myeloid leukemia (AML) patients with RARA overe... Full story

Yahoo Finance • 2 years ago

Syros Presents Safety Lead-in Data from SELECT-AML-1 Trial Evaluating Tamibarotene in Combination with Venetoclax and Azacitidine and Announces Plans to Initiate Randomized Portion of Phase 2 Trial

– 83% composite complete response rate in newly diagnosed unfit AML patients with RARA gene overexpression – - Initial safety and clinical activity profile of the triplet regimen supports advancing SELECT-AML-1 into the randomized portion... Full story

Yahoo Finance • 2 years ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLP Investigates HMTV, SYRS, SIMO

NEW YORK, July 21, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholde... Full story

Yahoo Finance • 2 years ago

Syros to Present at JMP Securities Life Sciences Conference

CAMBRIDGE, Mass., June 08, 2022--(BUSINESS WIRE)--Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, today announced that its Chief Executive Officer, Nancy Simonian, M.D., w... Full story

Yahoo Finance • 3 years ago

These 2 Penny Stocks Could Rally to $15 (Or More), Says Roth Capital

There are few stock segments more polarizing than the ‘pennies.’ These are low-cost equities, typically priced below $5 per share, and they elicit two distinct responses from investors. Some buyers can’t get away from the pennies fast enou... Full story

Yahoo Finance • 3 years ago

Syros Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

CAMBRIDGE, Mass., April 01, 2022--(BUSINESS WIRE)--Syros Pharmaceuticals (Nasdaq: SYRS), a leader in the development of medicines that control the expression of genes, today announced the grant of restricted stock unit (RSU) awards for an... Full story